Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025